2022
2021
2020
2019
2018
2017
2016
2015
2014
Tenax Therapeutics Reports Fiscal Year 2021 Results and Provides Business Update
Mar 31, 2022
Tenax Therapeutics Reports Fiscal Year 2021 Results and Provides Business Update
Mar 31, 2022
Tenax Therapeutics Announces Two Presentations at Upcoming American College of Cardiology Scientific Sessions
Mar 30, 2022
Tenax Therapeutics Appoints Robyn Hunter to the Board of Directors
Jan 31, 2022
Tenax Therapeutics Granted U.S. Patent for the Subcutaneous Use of Levosimendan (TNX-102)
Jan 12, 2022
Tenax Therapeutics Provides Update on TNX-102, TNX-103 and TNX-201 Clinical Programs
Jan 4, 2022